Acute myeloid leukemia experts share promising new developments on the oncology horizon.
Leukemia and Lymphoma
Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
Oncology is a complex and rapidly-evolving management challenge for payers.
Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.
Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.
Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.
Researchers see promising early clinical trials with checkpoint-inhibitor therapies, opening the door for checkpoint-blockade combo therapies.
How plans can achieve the right balance between cost and outcomes